Sign Out
In vitro evidence showed that the drug is metabolised through cytochrome P450 (CYP) 3A4 and aldoketoreductases (see Pharmacology: Pharmacokinetics under Actions) and does not inhibit any of the major CYP isoenzymes.
Exemestane should be used cautiously with drugs that are metabolised via CYP3A4 and have a narrow therapeutic window. There is no clinical experience of the concomitant use with other anticancer drugs.
Exemestane should not be co administered with oestrogen-containing medicines as these would negate its pharmacological action.
